ATE554763T1 - Photodynamische therapie der mit der altersbezogenen makuladegeneration verbundenen okkulten chorioidalen neovaskularisation - Google Patents

Photodynamische therapie der mit der altersbezogenen makuladegeneration verbundenen okkulten chorioidalen neovaskularisation

Info

Publication number
ATE554763T1
ATE554763T1 AT02703362T AT02703362T ATE554763T1 AT E554763 T1 ATE554763 T1 AT E554763T1 AT 02703362 T AT02703362 T AT 02703362T AT 02703362 T AT02703362 T AT 02703362T AT E554763 T1 ATE554763 T1 AT E554763T1
Authority
AT
Austria
Prior art keywords
age
occult
macular degeneration
related macular
chorioidal
Prior art date
Application number
AT02703362T
Other languages
English (en)
Inventor
H Strong
Mohammad Azad
Yong Hao
John Koester
Jr Troy Reaves
Original Assignee
Quadra Logic Tech Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc, Novartis Ag filed Critical Quadra Logic Tech Inc
Application granted granted Critical
Publication of ATE554763T1 publication Critical patent/ATE554763T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02703362T 2001-02-06 2002-02-06 Photodynamische therapie der mit der altersbezogenen makuladegeneration verbundenen okkulten chorioidalen neovaskularisation ATE554763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26694001P 2001-02-06 2001-02-06
PCT/US2002/003758 WO2002062386A2 (en) 2001-02-06 2002-02-06 Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration

Publications (1)

Publication Number Publication Date
ATE554763T1 true ATE554763T1 (de) 2012-05-15

Family

ID=23016614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02703362T ATE554763T1 (de) 2001-02-06 2002-02-06 Photodynamische therapie der mit der altersbezogenen makuladegeneration verbundenen okkulten chorioidalen neovaskularisation

Country Status (7)

Country Link
US (1) US8034803B2 (de)
EP (1) EP1357912B9 (de)
AT (1) ATE554763T1 (de)
AU (1) AU2002236988A1 (de)
CA (1) CA2437563C (de)
ES (1) ES2386718T3 (de)
WO (1) WO2002062386A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002234809B2 (en) * 2001-01-30 2005-04-07 Oncoquest Inc. Perylenequinones for use with immunotherapy agents
CA2437557C (en) * 2001-02-06 2012-07-24 Qlt Inc. Reduced total fluence photodynamic therapy of choroidal neovasculature in amd
US7753943B2 (en) 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
EP1357945A2 (de) 2001-02-06 2003-11-05 QLT Inc. Verfahren zur verhinderung von sehverlust
US7303578B2 (en) 2001-11-01 2007-12-04 Photothera, Inc. Device and method for providing phototherapy to the brain
US20050159793A1 (en) * 2002-07-02 2005-07-21 Jackson Streeter Methods for treating macular degeneration
WO2004034889A2 (en) * 2002-10-18 2004-04-29 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1605847B1 (de) * 2003-03-07 2009-09-16 Board Of Regents, The University Of Texas System Gegen antikörper gerichtete photodynamische therapie
US20060094753A1 (en) * 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
EP2186518A1 (de) * 2004-11-17 2010-05-19 McLaurin, Joanne Zusammensetzungen aus scyllo-inositol-derivaten und verfahren zur behandlung von störungen der proteinaggregation
CA2820233C (en) 2005-08-10 2015-09-08 Quest Pharmatech Inc. Perylenequinone derivatives and uses thereof
US20070111970A1 (en) * 2005-10-13 2007-05-17 Antonio Cruz Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence
WO2007129221A2 (en) * 2006-02-17 2007-11-15 Waratah Parmaceuticals Inc Compositions comprising an epi-inositol compounds and methods for treatment of disorders of protein aggregation
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
US20100113613A1 (en) * 2006-03-09 2010-05-06 Waratah Pharmaceuticals cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
US20110028719A1 (en) * 2006-05-19 2011-02-03 Jacek Slon-Usakiewicz Screening methods for amyloid beta modulators
US8454991B2 (en) 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
JP2010510254A (ja) * 2006-11-24 2010-04-02 ワラタ ファーマシューティカルズ， インコーポレイテッド アルツハイマー病および関連の神経変性疾患のための併用処置
US20100144891A1 (en) * 2007-04-12 2010-06-10 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
US20100331267A1 (en) * 2007-04-12 2010-12-30 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
EP2656839A1 (de) * 2007-04-12 2013-10-30 Waratah Pharmaceuticals, Inc. Verwendung von Cyclohexanehexolderivaten zur Behandlung von Augenerkrankungen
US20110105626A1 (en) * 2007-04-12 2011-05-05 Mclaurin Joanne Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
EP2349233A4 (de) * 2008-10-09 2012-04-18 Waratah Pharmaceuticals Inc Verwendung von scyllo-inositolen zur behandlung von makuladegenerationsbedingten erkrankungen
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
AU2015231439B2 (en) 2014-03-17 2019-11-14 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
WO2016094673A1 (en) * 2014-12-11 2016-06-16 Bayer Healthcare Llc Treatment of age related macular degeneration with a small active choroidal neovascularization lesion
KR20170137730A (ko) 2015-03-02 2017-12-13 애드베룸 바이오테크놀로지스, 인코포레이티드 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5935942A (en) 1994-12-14 1999-08-10 Zeimer; Ran Selective and non-invasive visualization or treatment of vasculature

Also Published As

Publication number Publication date
EP1357912B1 (de) 2012-04-25
US20030087889A1 (en) 2003-05-08
US8034803B2 (en) 2011-10-11
WO2002062386A2 (en) 2002-08-15
CA2437563A1 (en) 2002-08-15
EP1357912B9 (de) 2012-06-13
WO2002062386A3 (en) 2002-10-24
CA2437563C (en) 2010-03-23
EP1357912A2 (de) 2003-11-05
ES2386718T3 (es) 2012-08-28
AU2002236988A1 (en) 2002-08-19

Similar Documents

Publication Publication Date Title
ATE554763T1 (de) Photodynamische therapie der mit der altersbezogenen makuladegeneration verbundenen okkulten chorioidalen neovaskularisation
AR037307A1 (es) Metodos para el tratamiento de enfermedades oculares neovasculares
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
CY1110721T1 (el) Χρηση glp-2 σε συνδυασμο με αλλο θεραπευτικο παραγοντα σε οστικες παθησεις
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
SI1558616T2 (sl) Meso-substituirani porfirini
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
CY1106816T1 (el) 1,5-δισυποκαταστημενες ενωσεις 3,4-διυδρο-1h-πυριμιδο [4,5-d] πυριμιδιν-2-ονης και η χρησιμοποιηση αυτων δια τη θεραπευτικη αγωγη ασθενειων εις τις οποιες μεσολαβει η csbp/p38 κιναση
WO2002058730A3 (en) Compositions for treatment of ocular neovascularization
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
EP1381280A4 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
CY1108983T1 (el) Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων
WO2003032900A3 (en) Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
TR200402628T4 (tr) Androjenetik ve yaygın alopezinin tedavisinde melatonin maddesinin kullanımı
NO20024486D0 (no) Forbedret behandling av neovaskularisering
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
BRPI0407693A (pt) uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
WO2003028629A3 (en) Chlorin photosensitizing agents for use in photodynamic therapy
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
MXPA04007443A (es) Nuevos compuestos de porfirina-platino solubles en agua con alta selectividad tumoral y su uso para el tratamiento de enfermedades tumorales benignas y malignas.
WO2003028628A3 (en) Photosensitizing carbamate derivatives
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
AU2002234644A1 (en) Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases